Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Bryan J Donald, Salim Surani, Harmeet S Deol, Uche J Mbadugha & George Udeani. (2017) Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy. Drug Design, Development and Therapy 11, pages 3559-3566.
Read now
Read now
Bela Kocsis & Dora Szabo. (2017) New treatment options for lower respiratory tract infections. Expert Opinion on Pharmacotherapy 18:13, pages 1345-1355.
Read now
Read now
D. Leoni, B. Encina & J. Rello. (2016) Managing the oncologic patient with suspected pneumonia in the intensive care unit. Expert Review of Anti-infective Therapy 14:10, pages 943-960.
Read now
Read now
Françoise Van Bambeke & Paul M. Tulkens. (2016) The role of solithromycin in the management of bacterial community-acquired pneumonia. Expert Review of Anti-infective Therapy 14:3, pages 311-324.
Read now
Read now
Travis M Jones, Steven W Johnson, V Paul DiMondi & Dustin T Wilson. (2016) Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Infection and Drug Resistance 9, pages 119-128.
Read now
Read now
Articles from other publishers (20)
Muhammad Shoaib, Amjad Islam Aqib, Iqra Muzammil, Noreen Majeed, Zeeshan Ahmad Bhutta, Muhammad Fakhar-e-Alam Kulyar, Mahreen Fatima, C-Neen Fatima Zaheer, Afshan Muneer, Maheen Murtaza, Muhammad Kashif, Furqan Shafqat & Wanxia Pu. (2023) MRSA compendium of epidemiology, transmission, pathophysiology, treatment, and prevention within one health framework. Frontiers in Microbiology 13.
Crossref
Crossref
Johanne Blais, Charles R. Dean, Guillaume Lapointe, Jennifer A. Leeds, Sylvia Ma, Laura Morris, Heinz E. Moser, Colin S. Osborne, Katherine R. Prosen, Daryl Richie, Colin Skepper, Katherine Thompson, Jason Vo, Qin Yue & Alexey Rivkin. (2022)
In Vitro
and
In Vivo
Properties of CUO246, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor
. Antimicrobial Agents and Chemotherapy 66:12.
Crossref
Crossref
Béla Kocsis, Dániel Gulyás & Dóra Szabó. (2021) Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics 10:12, pages 1506.
Crossref
Crossref
Brandon A. Byrd, Blesing Zenick, Maria C. Rocha-Granados, Hanna E. Englander, Patricia J. Hare, Travis J. LaGree, Angela M. DeMarco & Wendy W. K. Mok. (2021) The AcrAB-TolC Efflux Pump Impacts Persistence and Resistance Development in Stationary-Phase Escherichia coli following Delafloxacin Treatment. Antimicrobial Agents and Chemotherapy 65:8.
Crossref
Crossref
忠秋 郭. (2019) Delafloxacin: A Novel Fluoroquinolones Broad-Spectrum Antibacterial. Pharmacy Information 08:01, pages 9-15.
Crossref
Crossref
M. A. Pfaller, R. K. Flamm, S. P. McCurdy, C. M. Pillar, D. Shortridge & R. N. Jones. (2018)
Delafloxacin
In Vitro
Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone
. Journal of Clinical Microbiology 56:8.
Crossref
Crossref
A.M. Bal, M.Z. David, J. Garau, T. Gottlieb, T. Mazzei, F. Scaglione, P. Tattevin & I.M. Gould. (2017) Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen. Journal of Global Antimicrobial Resistance 10, pages 295-303.
Crossref
Crossref
Muhammad-Hariri Mustafa, Shaunak Khandekar, Michael M. Tunney, J. Stuart Elborn, Barbara C. Kahl, Olivier Denis, Patrick Plésiat, Hamidou Traore, Paul M. Tulkens, Francis Vanderbist & Françoise Van Bambeke. (2017)
Acquired resistance to macrolides in
Pseudomonas aeruginosa
from cystic fibrosis patients
. European Respiratory Journal 49:5, pages 1601847.
Crossref
Crossref
M. A. Pfaller, H. S. Sader, P. R. Rhomberg & R. K. Flamm. (2017)
In Vitro
Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014
. Antimicrobial Agents and Chemotherapy 61:4.
Crossref
Crossref
Zsolt Szűcs, Magdolna Csávás, Erzsébet Rőth, Anikó Borbás, Gyula Batta, Florent Perret, Eszter Ostorházi, Réka Szatmári, Evelien Vanderlinden, Lieve Naesens & Pál Herczegh. (2016) Synthesis and biological evaluation of lipophilic teicoplanin pseudoaglycon derivatives containing a substituted triazole function. The Journal of Antibiotics 70:2, pages 152-157.
Crossref
Crossref
Françoise van Bambeke, Marie-Paule Mingeot-Leclercq, Youri Glupczynski & Paul M. Tulkens. 2017. Infectious Diseases. Infectious Diseases
1162
1180.e1
.
Bela Kocsis, J. Domokos & D. Szabo. (2016) Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Annals of Clinical Microbiology and Antimicrobials 15:1.
Crossref
Crossref
George G. Zhanel, Erika Hartel, Heather Adam, Sheryl Zelenitsky, Michael A. Zhanel, Alyssa Golden, Frank Schweizer, Bala Gorityala, Philippe R. S. Lagacé-Wiens, Andrew J. Walkty, Alfred S. Gin, Daryl J. Hoban, Joseph P. LynchIIIIII & James A. Karlowsky. (2016) Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs 76:18, pages 1737-1757.
Crossref
Crossref
Mathieu F. Chellat, Luka Raguž & Rainer Riedl. (2016) Targeting Antibiotic Resistance. Angewandte Chemie International Edition 55:23, pages 6600-6626.
Crossref
Crossref
Mathieu F. Chellat, Luka Raguž & Rainer Riedl. (2016) Antibiotikaresistenzen gezielt überwinden. Angewandte Chemie 128:23, pages 6710-6738.
Crossref
Crossref
Dirk KochDirk Koch. 2016. HNO Fragen und Antworten. HNO Fragen und Antworten
85
134
.
W.V. Kern. (2015) Neue Antibiotika auf dem Markt und in EntwicklungNew antibacterial agents on the market and in the pipeline. Der Internist 56:11, pages 1255-1263.
Crossref
Crossref
Françoise Van Bambeke. (2015) Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiology 10:7, pages 1111-1123.
Crossref
Crossref
Nathalie M. Vandevelde, Paul M. Tulkens, Giulio G. Muccioli & Françoise Van Bambeke. (2015)
Modulation of the activity of moxifloxacin and solithromycin in an
in vitro
pharmacodynamic model of
Streptococcus pneumoniae
naive and induced biofilms
. Journal of Antimicrobial Chemotherapy 70:6, pages 1713-1726.
Crossref
Crossref
R. Draenert, U. Seybold, E. Grützner & J. R. Bogner. (2015) Novel antibiotics: Are we still in the pre–post-antibiotic era?. Infection 43:2, pages 145-151.
Crossref
Crossref